TABLE 152: VIRAL LOAD ≥ THRESHOLD GENOTYPE 1 TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + LDV24	SOF12 + LDV12	1.04 (0.98 to 1.10)	3.42 (−1.48 to 8.92)
SOF12 + LDV12 + RBV12		1.03 (0.98 to 1.10)	2.91 (−2.01 to 8.47)
SOF24 + LDV24 + RBV24		1.05 (1.00 to 1.11)	4.46 (−0.05 to 9.91)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.03 (0.91 to 1.10)	2.64 (−8.26 to 8.64)
DCV24 + ASU24		0.92 (0.67 to 1.04)	−7.28 (−30.94 to 3.27)
DCV24 + ASU24 + PR24		0.99 (0.58 to 1.08)	−0.95 (−39.66 to 7.50)
SOF12 + PR12		0.91 (0.56 to 1.04)	−8.62 (−41.17 to 3.44)
SOF12 + LDV12 + RBV12	SOF24 + LDV24	1.00 (0.96 to 1.03)	−0.45 (−3.99 to 2.87)
SOF24 + LDV24 + RBV24		1.01 (0.97 to 1.06)	1.06 (−2.68 to 5.17)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.99 (0.89 to 1.03)	−0.53 (−10.64 to 3.24)
DCV24 + ASU24		0.89 (0.65 to 0.98)	−10.61 (−33.78 to −1.52)
DCV24 + ASU24 + PR24		0.96 (0.56 to 1.03)	−4.16 (−43.40 to 2.91)
SOF12 + PR12		0.88 (0.55 to 0.99)	−11.96 (−44.07 to −1.21)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.02 (0.98 to 1.06)	1.48 (−2.05 to 5.72)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.00 (0.91 to 1.03)	−0.09 (−8.95 to 2.64)
DCV24 + ASU24		0.89 (0.67 to 0.98)	−10.20 (−31.58 to −2.25)
DCV24 + ASU24 + PR24		0.96 (0.56 to 1.04)	−3.72 (−42.50 to 3.55)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + PR12		0.88 (0.56 to 0.98)	−11.48 (−42.25 to −1.71)
PAR/RIT12 + OMB12 + DAS12 + RBV12	SOF24 + LDV24 + RBV24	0.98 (0.88 to 1.02)	−1.57 (−12.24 to 2.20)
DCV24 + ASU24		0.88 (0.64 to 0.98)	−11.75 (−35.44 to −1.79)
DCV24 + ASU24 + PR24		0.95 (0.56 to 1.00)	−5.30 (−42.92 to −0.19)
SOF12 + PR12		0.87 (0.53 to 0.98)	−13.07 (−46.03 to −1.79)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.90 (0.67 to 0.99)	−9.53 (−31.00 to −0.64)
DCV24 + ASU24 + PR24		0.97 (0.57 to 1.09)	−3.28 (−41.48 to 7.79)
SOF12 + PR12		0.89 (0.56 to 1.00)	−10.84 (−42.00 to 0.35)
DCV24 + ASU24 + PR24	DCV24 + ASU24	1.06 (0.64 to 1.46)	5.56 (−32.01 to 29.93)
SOF12 + PR12		0.99 (0.66 to 1.27)	−1.23 (−28.96 to 18.36)
SOF12 + PR12	DCV24 + ASU24 + PR24	0.93 (0.58 to 1.53)	−6.51 (−39.96 to 30.29)
Random effect model	Residual deviance	16.3 vs. 18 data points	
	Deviance information criteria	89.512	
Fixed effect model	Residual deviance	16.03 vs. 18 data points	
	Deviance information criteria	88.713	

ASU = asunaprevir; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; LDV = ledipasvir; OMB = ombitasvir;
PAR = paritaprevir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RIT = ritonavir; RR = relative risk;
SIM = simeprevir; SOF = sofosbuvir; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.